Kraig Biocraft's Losses Widen Amidst Zero Revenue, Equity Infusion Boosts Cash

TL;DR

**KBLB is burning cash with no revenue in sight; this is a speculative bet on future tech, not a current business.**

AI Summary

Kraig Biocraft Laboratories, Inc. reported a net loss of $2,835,732 for the nine months ended September 30, 2025, an increase from the $2,547,264 net loss in the same period of 2024. The company generated no revenue in either period. Total operating expenses rose to $2,652,125 for the nine months ended September 30, 2025, up from $2,358,645 in 2024, primarily driven by a significant increase in General and Administrative expenses from $1,467,411 in 2024 to $1,852,841 in 2025. Cash and cash equivalents increased substantially to $1,565,692 as of September 30, 2025, from $673,264 at December 31, 2024, largely due to $1,925,702 in proceeds from a Standby Equity Purchase Agreement. The company's accumulated deficit grew to $55,921,451 by September 30, 2025, from $53,085,719 at December 31, 2024, indicating continued operational losses. Related party liabilities remain high, with accounts payable and accrued expenses - related party totaling $8,004,099. The company continues to invest in its Vietnamese subsidiary, Prodigy Textiles Co., Ltd., having received a new Investment Registration Certificate and Enterprise Registration Certificate on January 14, 2025, to enhance sericulture through spider silk silkworm technology.

Why It Matters

For investors, KBLB's continued lack of revenue and widening net losses, despite a cash injection from a Standby Equity Purchase Agreement, signals significant operational challenges and a high-risk profile. The substantial increase in General and Administrative expenses without corresponding revenue generation raises questions about cost control and path to commercialization. Employees might face uncertainty given the company's persistent unprofitability, while customers are yet to see widespread commercial application of its spider silk technology, potentially impacting future market adoption. In a competitive landscape for advanced materials, KBLB's slow progress in commercializing its recombinant DNA technology could allow competitors to gain an advantage, making its strategic outlook precarious.

Risk Assessment

Risk Level: high — The company reported zero revenue for both the three and nine months ended September 30, 2025, and 2024, while incurring a net loss of $2,835,732 for the nine months ended September 30, 2025. This persistent lack of revenue combined with increasing operating expenses, including $1,852,841 in General and Administrative costs, indicates a high operational risk and reliance on external financing, such as the $1,925,702 from the Standby Equity Purchase Agreement, to sustain operations.

Analyst Insight

Investors should approach KBLB with extreme caution, recognizing it as a highly speculative investment. Given the absence of revenue and widening losses, potential investors should only consider a small, high-risk allocation if they have a strong conviction in the long-term commercial viability of its spider silk technology and are prepared for significant capital loss.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$(2,835,732)

eps

N/A

gross Margin

N/A

cash Position

$1,565,692

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the nine months ended September 30, 2025, or 2024.)
• $(2,835,732) — Net Loss (Increased from $(2,547,264) in 2024 for the nine months ended September 30.)
• $1,565,692 — Cash and Cash Equivalents (Increased from $673,264 at December 31, 2024, primarily due to equity financing.)
• $1,852,841 — General and Administrative Expenses (Increased from $1,467,411 in 2024 for the nine months ended September 30.)
• $1,925,702 — Proceeds from Standby Equity Purchase Agreement (Key financing activity for the nine months ended September 30, 2025.)
• $(55,921,451) — Accumulated Deficit (Grew from $(53,085,719) at December 31, 2024, reflecting ongoing losses.)
• $8,004,099 — Accounts payable and accrued expenses - related party (Significant related party liability as of September 30, 2025.)
• 1,076,244,777 — Class A Common Stock Outstanding (Increased from 1,038,374,219 shares at December 31, 2024, indicating dilution.)

Key Players & Entities

• Kraig Biocraft Laboratories, Inc. (company) — registrant
• Prodigy Textiles Co., Ltd. (company) — Vietnamese subsidiary
• Vietnam Sericulture Association (company) — partner in memorandum of understanding
• Lam Dong Agro-Forestry Research & Experiment Center (company) — partner in memorandum of understanding
• Hunter Taubman Fischer & Li LLC (company) — legal counsel
• SEC (regulator) — Securities and Exchange Commission
• $2,835,732 (dollar_amount) — net loss for nine months ended September 30, 2025
• $1,925,702 (dollar_amount) — proceeds from Standby Equity Purchase Agreement
• $1,565,692 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $8,004,099 (dollar_amount) — accounts payable and accrued expenses - related party as of September 30, 2025

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company has incurred significant losses and has an accumulated deficit of $55,921,451 as of September 30, 2025. It relies on external financing, such as the Standby Equity Purchase Agreement which provided $1,925,702, to fund its operations. Without continued access to capital, the company may not be able to continue as a going concern.
• Lack of Revenue Generation [high — operational]: Kraig Biocraft Laboratories has generated no revenue in the nine months ended September 30, 2025, and 2024. This lack of commercialization indicates significant challenges in bringing its spider silk technology to market and generating sales.
• High Related Party Liabilities [medium — financial]: As of September 30, 2025, the company has $8,004,099 in accounts payable and accrued expenses owed to related parties. This concentration of debt with related parties could pose risks if these parties demand repayment or if conflicts of interest arise.
• Increasing Operating Expenses [medium — operational]: Total operating expenses increased to $2,652,125 for the nine months ended September 30, 2025, from $2,358,645 in the prior year period. The primary driver was a rise in General and Administrative expenses from $1,467,411 to $1,852,841, indicating increasing overhead without corresponding revenue growth.
• Regulatory Compliance for New Technologies [medium — regulatory]: The company's focus on novel materials like spider silk may involve navigating complex and evolving regulatory landscapes for product approval and market entry, especially in international markets like Vietnam where its subsidiary operates.
• Shareholder Dilution [medium — financial]: The issuance of new shares, evidenced by the increase in Class A Common Stock Outstanding from 1,038,374,219 at December 31, 2024, to 1,076,244,777 as of September 30, 2025, suggests ongoing equity financing which dilutes existing shareholders' ownership percentage.

Industry Context

The biotechnology and advanced materials sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Kraig Biocraft Laboratories are attempting to disrupt traditional material markets with novel solutions, such as spider silk, but face intense competition from established players and the need to prove commercial viability and scalability.

Regulatory Implications

The company's operations, particularly its subsidiary in Vietnam, are subject to local and international regulations concerning manufacturing, environmental impact, and product safety. Obtaining and maintaining necessary certifications, like the recent Investment Registration Certificate, is critical for continued operations and market access.

What Investors Should Do

1. Monitor revenue generation closely.
2. Evaluate the sustainability of financing.
3. Assess the progress of the Vietnamese subsidiary.
4. Scrutinize increases in General and Administrative expenses.

Key Dates

• 2025-01-14: Received new Investment Registration Certificate and Enterprise Registration Certificate for Prodigy Textiles Co., Ltd. — This signifies regulatory approval and formal establishment for the company's Vietnamese subsidiary, crucial for its sericulture and spider silk technology development in the region.

Glossary

Accumulated Deficit

The total net losses a company has incurred since its inception, minus any net income. It represents the cumulative loss that has not been offset by profits. (Kraig Biocraft Laboratories has a substantial accumulated deficit of $55,921,451, highlighting its history of unprofitability and reliance on external funding.)

Standby Equity Purchase Agreement

A financing arrangement where a company has the right, but not the obligation, to sell shares of its stock to an investor at a predetermined price over a specified period. (The company raised $1,925,702 through such an agreement, which is a key source of its current cash balance and indicates its need for ongoing capital infusion.)

Sericulture

The cultivation of silkworms to produce silk. (This is the core activity of Kraig Biocraft's Vietnamese subsidiary, Prodigy Textiles, focusing on advanced silkworm technology for spider silk production.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Kraig Biocraft Laboratories reported an increased net loss of $2,835,732 compared to $2,547,264 in the same period of 2024, with no revenue generated in either period. Operating expenses rose, driven by a substantial increase in General and Administrative expenses. While cash reserves improved significantly to $1,565,692 due to equity financing, the accumulated deficit also grew, underscoring the company's continued unprofitability and reliance on external capital.

Filing Documents

• form10-q.htm (10-Q) — 1574KB
• ex31-1.htm (EX-31.1) — 15KB
• ex31-2.htm (EX-31.2) — 15KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-25-021953.txt ( ) — 8646KB
• kblb-20250930.xsd (EX-101.SCH) — 65KB
• kblb-20250930_cal.xml (EX-101.CAL) — 58KB
• kblb-20250930_def.xml (EX-101.DEF) — 299KB
• kblb-20250930_lab.xml (EX-101.LAB) — 531KB
• kblb-20250930_pre.xml (EX-101.PRE) — 418KB
• form10-q_htm.xml (XML) — 1539KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 40

Controls and Procedures

Item 4. Controls and Procedures 40

OTHER INFORMATION

PART II OTHER INFORMATION

Legal proceedings

Item 1. Legal proceedings 41

Risk Factors

Item 1A. Risk Factors 41

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41

Defaults upon Senior Securities

Item 3. Defaults upon Senior Securities 41

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 41

Other information

Item 5. Other information 41

Exhibits

Item 6. Exhibits 42 2 Kraig Biocraft Laboratories, Inc. and Subsidiary Condensed Consolidated Balance Sheets September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 1,565,692 $ 673,264 Inventory 29,067 6,884 Prepaid expenses 45,162 60,137 Total Current Assets 1,639,921 740,285 Property and Equipment, net 30,993 44,721 Investment in gold bullions (cost $ 241,120 and $ 450,216 , respectively) 494,478 627,065 Operating lease right-of-use asset, net 184,030 86,088 Security deposit 7,174 7,174 Total Assets $ 2,356,596 $ 1,505,333 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses $ 492,252 $ 502,002 Note payable - related party 1,567,000 1,617,000 Royalty agreement payable - related party 65,292 65,292 Accounts payable and accrued expenses - related party 8,004,099 7,383,186 Accounts payable and accrued expenses 8,004,099 7,383,186 Operating lease liability, current 56,062 46,948 Total Current Liabilities 10,184,705 9,614,428 Long Term Liabilities Operating lease liability, net of current 127,968 40,526 Total Liabilities 10,312,673 9,654,954 Commitments and Contingencies (Note 9) - - Stockholders' Deficit Preferred stock, no par value; unlimited shares authorized, none , issued and outstanding - - Preferred stock Series A, no par value; 3 and 3 shares issued and outstanding, respectively 5,237,800 5,237,800 Preferred stock value 5,237,800 5,237,800 Common stock Class A, no par value; unlimited shares authorized, 1,076,244,777 and 1,038,374,219 shares issued and outstanding, respectively 30,363,230 27,385,611 Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding - - Common stock value - - Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively 22,000 22,000 Additional paid-in capital 12,342,344 12,290

View Full Filing

View this 10-Q filing on SEC EDGAR